

Florian M Freimoser

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/342342/publications.pdf>

Version: 2024-02-01

17
papers

971
citations

933447

10
h-index

996975

15
g-index

19
all docs

19
docs citations

19
times ranked

1538
citing authors

#	ARTICLE	IF	CITATIONS
1	JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy. , 2022, 10, e003766.		15
2	Fibroblast Activation Protein $\hat{\pm}$ -Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity. <i>Clinical Cancer Research</i> , 2021, 27, 4036-4053.	7.0	31
3	Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies. <i>ELife</i> , 2021, 10, .	6.0	33
4	Fc $\hat{\pm}$ R1IIa chromatography to enrich a-fucosylated glycoforms and assess the potency of glycoengineered therapeutic antibodies. <i>Journal of Chromatography A</i> , 2020, 1610, 460554.	3.7	11
5	Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody. <i>Nature Communications</i> , 2020, 11, 3196.	12.8	43
6	P329G-CAR-J: a novel Jurkat-NFAT-based CAR-T reporter system recognizing the P329G Fc mutation. <i>Protein Engineering, Design and Selection</i> , 2019, 32, 207-218.	2.1	6
7	Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	178
8	CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2018, 24, 4785-4797.	7.0	146
9	A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease. <i>Journal of Autoimmunity</i> , 2018, 95, 1-14.	6.5	129
10	p95HER2 $\hat{\pm}$ T cell bispecific antibody for breast cancer treatment. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	59
11	Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. <i>OncImmunology</i> , 2017, 6, e1277306.	4.6	190
12	CD20 Tcb (RG6026), a Novel "2:1" T Cell Bispecific Antibody for the Treatment of B Cell Malignancies. <i>Blood</i> , 2016, 128, 1836-1836.	1.4	22
13	Abstract 2217: Combining CEA-IL2v and FAP-IL2v immunocytokines with PD-L1 checkpoint blockade. <i>Cancer Research</i> , 2016, 76, 2217-2217.	0.9	3
14	Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells. <i>Journal of Autoimmunity</i> , 2015, 56, 66-80.	6.5	87
15	Abstract 2592: Tumor targeting and pharmacodynamics of the novel targeted immunocytokine FAP-IL2v in a tumor-bearing Rhesus monkey. , 2014, , .		1
16	Abstract 486: Tumor-targeted, engineered IL-2 variant (IL-2v)-based immunocytokines for the immunotherapy of cancer.. <i>Cancer Research</i> , 2013, 73, 486-486.	0.9	6
17	In Vitro Cultivation of the Entomopathogenic Fungus <i>Entomophthora thripidum</i> : Isolation, Growth Requirements, and Sporulation. <i>Mycologia</i> , 2000, 92, 208.	1.9	9